Category: Psychedelic Bulletin - Page 13 - Psychedelic Alpha

Read more about the article Psychedelic Bulletin: Delix Raises $70m Series A; Toronto Gets Psychedelics Research Centre; Elon Musk Endorses Psychedelics

Psychedelic Bulletin: Delix Raises $70m Series A; Toronto Gets Psychedelics Research Centre; Elon Musk Endorses Psychedelics

Post published:October 1, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Are REMS Patents the Next Frontier in the Psychedelics Patent Skirmish? Johns Hopkins Researcher Scores U.S. Government Grant

Psychedelic Bulletin: Are REMS Patents the Next Frontier in the Psychedelics Patent Skirmish? Johns Hopkins Researcher Scores U.S. Government Grant

Post published:September 24, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: COMPASS Pathways Acquires IP Portfolio; Wesana to Explore MDMA for TBI With MAPS; Nine Perfect Strangers Draws Attention to Psychedelics

Psychedelic Bulletin: COMPASS Pathways Acquires IP Portfolio; Wesana to Explore MDMA for TBI With MAPS; Nine Perfect Strangers Draws Attention to Psychedelics

Post published:September 17, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Proliferation of Psilocybin-Related Drug Development; Biden-Harris Administration Aims to Reduce Barriers to Schedule I Research

Psychedelic Bulletin: Proliferation of Psilocybin-Related Drug Development; Biden-Harris Administration Aims to Reduce Barriers to Schedule I Research

Post published:September 10, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: DEA Proposes Increase to Psilocybin Quota; Field Trip Launches KAP Co-Operative Program; MindMed Files DTx Patent Application

Psychedelic Bulletin: DEA Proposes Increase to Psilocybin Quota; Field Trip Launches KAP Co-Operative Program; MindMed Files DTx Patent Application

Post published:September 3, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: California Decrim. Bill Put on Pause; MindMed Inks Real-World Evidence Collaboration

Psychedelic Bulletin: California Decrim. Bill Put on Pause; MindMed Inks Real-World Evidence Collaboration

Post published:August 27, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Beckley Psytech Raises $80m in Series B; Bright Minds Biosciences Reports Positive Preclinical Findings; Psychedelics DNA Test Called Into Question

Psychedelic Bulletin: Beckley Psytech Raises $80m in Series B; Bright Minds Biosciences Reports Positive Preclinical Findings; Psychedelics DNA Test Called Into Question

Post published:August 20, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: Compass Pathways Secures 5th Patent; atai to Develop Salvinorin A

Psychedelic Bulletin: Compass Pathways Secures 5th Patent; atai to Develop Salvinorin A

Post published:August 13, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: UK Patent Examiner Questions Compass Patent; Canadians Overwhelmingly Support Psilocybin Policy Reform; No Data Protection for Spravato in Canada

Psychedelic Bulletin: UK Patent Examiner Questions Compass Patent; Canadians Overwhelmingly Support Psilocybin Policy Reform; No Data Protection for Spravato in Canada

Post published:August 6, 2021
Post category:Psychedelic Bulletin

Read more about the article Psychedelic Bulletin: MindMed Initiates DMT Trial; COMPASS Appoints CMO; Field Trip Lists on NASDAQ

Psychedelic Bulletin: MindMed Initiates DMT Trial; COMPASS Appoints CMO; Field Trip Lists on NASDAQ

Post published:July 30, 2021
Post category:Psychedelic Bulletin

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.